ATE285418T1 - Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation - Google Patents

Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation

Info

Publication number
ATE285418T1
ATE285418T1 AT99972646T AT99972646T ATE285418T1 AT E285418 T1 ATE285418 T1 AT E285418T1 AT 99972646 T AT99972646 T AT 99972646T AT 99972646 T AT99972646 T AT 99972646T AT E285418 T1 ATE285418 T1 AT E285418T1
Authority
AT
Austria
Prior art keywords
hbv
surface antigen
preparation
humanized antibody
antibody specific
Prior art date
Application number
AT99972646T
Other languages
English (en)
Inventor
Hyo Jeong Hong
Chun Jeih Ryu
Hyangsuk Hur
Original Assignee
Korea Inst Sci & Tech
Green Cross Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Sci & Tech, Green Cross Korea filed Critical Korea Inst Sci & Tech
Application granted granted Critical
Publication of ATE285418T1 publication Critical patent/ATE285418T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT99972646T 1998-11-19 1999-11-19 Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation ATE285418T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980049663A KR100345463B1 (ko) 1998-11-19 1998-11-19 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
PCT/KR1999/000699 WO2000031141A1 (en) 1998-11-19 1999-11-19 Humanized antibody specific for surface antigen pre-s1 of hbv and preparation method thereof

Publications (1)

Publication Number Publication Date
ATE285418T1 true ATE285418T1 (de) 2005-01-15

Family

ID=37037248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972646T ATE285418T1 (de) 1998-11-19 1999-11-19 Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation

Country Status (8)

Country Link
US (1) US7115723B1 (de)
EP (1) EP1131358B1 (de)
JP (1) JP3552103B2 (de)
KR (1) KR100345463B1 (de)
AT (1) ATE285418T1 (de)
CA (1) CA2351315C (de)
DE (1) DE69922834D1 (de)
WO (1) WO2000031141A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2362098C (en) * 1999-02-05 2011-10-11 Jens-Ulrich Bulow Human polyclonal antibodies from genetically engineered animals
EP1604997A1 (de) * 1999-02-05 2005-12-14 Therapeutic Human Polyclonals, Inc. Aus nicht-menschlichen transgenen Tieren gewonnene menschliche polyklonale Antikörper
CN1395617A (zh) * 2000-10-02 2003-02-05 韩国生命工学研究院 抗乙肝病毒表面抗原s的人源化抗体及其制备方法
KR100455902B1 (ko) * 2001-07-18 2004-11-12 주식회사 펩트론 Ｂ형 간염 바이러스 표면단백질 프리에스-1 유래의 펩타이드
AU2003210060B2 (en) * 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
CN100582781C (zh) * 2006-06-27 2010-01-20 厦门大学 联合检测hbv前s1抗原和核心抗原的方法及诊断试剂盒
PE20081216A1 (es) 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
KR101864693B1 (ko) * 2014-11-27 2018-06-07 진원생명과학 주식회사 B형 간염 바이러스의 preS1에 특이적으로 결합하는 항체 및 이의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN117247944A (zh) * 2015-05-22 2023-12-19 华辉安健（北京）生物科技有限公司 抗前-s1 hbv抗体
JP2022542035A (ja) * 2019-07-20 2022-09-29 フアフイ ヘルス リミテッド 抗ｐｒｅ－ｓ１ ｈｂｖ抗体を用いるｈｂｖ感染症の治療方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202796D0 (en) * 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody

Also Published As

Publication number Publication date
CA2351315C (en) 2006-01-24
WO2000031141B1 (en) 2000-07-20
KR100345463B1 (ko) 2003-01-08
KR20000033008A (ko) 2000-06-15
JP2002531073A (ja) 2002-09-24
EP1131358B1 (de) 2004-12-22
US7115723B1 (en) 2006-10-03
DE69922834D1 (de) 2005-01-27
CA2351315A1 (en) 2000-06-02
JP3552103B2 (ja) 2004-08-11
EP1131358A1 (de) 2001-09-12
WO2000031141A1 (en) 2000-06-02

Similar Documents

Publication Publication Date Title
DE69938054D1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ATE222928T1 (de) Humanisierte antikörper gegen cd38
ZA95786B (en) Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 recombinant mage-1 and mage-1 derived immunogeni peptides
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
DK0699755T3 (da) Fremgangsmåde til opnåelse af modificerede immunglobuliner med reduceret immunogenicitet af variable domæner i et murint antistof, præparater der indeholder disse
MX9602971A (es) Anticuerpos humanizados contra la molecula vla-4 de adhesion de leucocitos.
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
MY154009A (en) Anti-alpha v beta 6 antibodies
DK0853633T3 (da) Humant monoklonalt antistof imod hepatitis B virus overfladeantigen (HBVsAg)
NZ296564A (en) Method of improving antigenicity of antigens or haptens, fusion with rsv peptides; vaccines, vectors, nucleotides
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
WO1995021922A3 (en) Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
GB0309126D0 (en) Clostridium difficile focussed antibodies
WO2002060954A8 (en) Materials and methods for treatment of hepatitis c
EP1326895B8 (de) Monoklonale antikörper gegen hepatitis b virus
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
RU93004854A (ru) Пептиды для вакцинации и индукции нейтрализующих антител против вируса иммунодефицита человека

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties